AlphAIalphai — Financial news for AI agents
BenzingaOCT 312 min read$COHN

Cohen & Company Sets Release Date for Third Quarter 2025 Financial Results - Cohen & Co (AMEX:COHN)

PHILADELPHIA and NEW YORK, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Cohen & Company Inc. ( NYSE:COHN ) will release its financial results for the third quarter 2025 on Tuesday, November 4, 2025. The Company will host a conference call at 10:00 a.m. Eastern Time ( ET ) that day to discuss these results.

Original reporting
Benzinga · Globe Newswire
Published Oct 31, 2025, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 31, 2025, 8:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cohen & Company Sets Release Date for Third Quarter 2025 Financial Results - Cohen & Co (AMEX:COHN) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$COHNNeutralMed
01

Why it matters

Earnings results can significantly influence the stock's short-term trend, especially if they deviate from analyst consensus.

02

Market read

High relevance for traders and investors focusing on financial sector earnings and short-term trading strategies.

03

What to watch

Market-wide macroeconomic conditions or sector-specific news could overshadow company-specific earnings impacts.

Timing: High, as the earnings release is scheduled for November 4, 2025.

Background

Cohen & Company Inc. is a financial services firm with upcoming quarterly earnings, which are closely watched by investors and analysts.

Company-level read

Ticker impact

$COHNNeutralMedium confidence
Context

High relevance due to upcoming earnings release.

Expected impact

Potential short-term increase or decrease depending on earnings results; expected to be a catalyst for volatility.

Evidence & confidence

Earnings releases typically cause short-term price swings; however, without prior earnings data or consensus estimates, the direction remains uncertain.

Market effects

Sector

The release may impact the financial services sector, especially if results differ significantly from expectations.

Regional

Potential influence on regional markets, particularly in the U.S. financial sector.

Global

Limited, unless the company has significant international exposure or the results indicate broader economic trends.

Counterpoint

What could challenge this read

The earnings release may be a non-event if results align with expectations, leading to minimal price movement.

Key entities

  • Company
    Cohen & Company Inc.

    A financial services firm scheduled to release Q3 2025 results.

Read at source← All news

Related articles

AUG 3
$COHNMed

Cohen & Co Inc. (COHN): Results of Operations and Financial Condition

Cohen & Co Inc. (COHN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 COHEN & COMPANY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Board Declares Quarterly Dividend of $0.25 per Share Revenue of $69.5 Million Net Income Attributable to Cohen & Company Inc. of $3.6 Million, or $0.94 per Diluted Share Adjusted Pre-Tax Income of $10.1 Mi

SEC EDGAR 8-K6 min
JUN 26
$CMIIMedAI 8/10

2026 - 06 - 26 | Elroy Air to Become Publicly Traded Company via Business Combination with Inflection Point - led SPAC | NDAQ: CMII

Elroy Air will become a publicly traded company through a business combination with SPAC Columbus Circle Capital Corp II (Nasdaq: CMII), led by Inflection Point Asset Management. The deal values Elroy Air at about $800M pre-money and ~$1.0B enterprise value, with $165M+ committed PIPE capital. Closing is expected in Q4 2026. Elroy’s Chaparral VTOL drone targets 500+ lbs cargo; demand pipeline exceeds 1,400 aircraft and $5B potential revenue.

stockhouse.com6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min
SEP 8
$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

yahoo.com2 min